Lineage Cell Therapeutics, Inc. Payments to Acquire Marketable Securities
Lineage Cell Therapeutics, Inc. (LCTX) reported Payments to Acquire Marketable Securities of $18.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $10.43M.
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $8.24M.
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $14.94M.
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $14.94M, a 70.47% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $8.76M, a 46.59% decline from fiscal 2023.
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $16.40M, a 69.29% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $53.41M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $18.66M 10-Q · filed 2026-08-06 | $33.60M derived: sum of 3 quarters · filed 2026-08-06 | $33.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.24M 10-Q · filed 2026-05-12 | $23.17M derived: sum of 2 quarters · filed 2026-05-12 | $23.17M derived: sum of 3 quarters · filed 2026-05-12 | $23.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $14.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $14.94M derived: sum of 2 quarters · filed 2026-03-05 | $14.94M derived: sum of 3 quarters · filed 2026-08-06 | $14.94M 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $8.76M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $8.76M derived: sum of 3 quarters · filed 2026-03-05 | $8.76M 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.76M derived: sum of 2 quarters · filed 2025-11-06 | $8.76M 10-Q · filed 2025-11-06 | $8.76M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $8.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $8.76M 10-Q · filed 2025-08-12 | $8.76M derived: sum of 3 quarters · filed 2025-08-12 | $12.53M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $3.77M derived: sum of 3 quarters · filed 2025-03-10 | $8.69M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $3.77M derived: sum of 2 quarters · filed 2025-03-10 | $8.69M derived: sum of 3 quarters · filed 2025-03-10 | $16.40M 10-K · filed 2025-03-10 |
| 2023-09-30 | $3.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $8.69M derived: sum of 2 quarters · filed 2024-11-14 | $16.40M 10-Q · filed 2024-11-14 | $29.19M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $4.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $12.63M 10-Q · filed 2024-08-08 | $25.42M derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $7.72M 10-Q · filed 2024-05-09 | $20.50M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $12.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $53.41M 10-K · filed 2024-03-07 | ||
| 2022-09-30 | $40.63M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |